MIA-15-5

antibody to the human H antigen (Fuc alpha1-2Gal beta1-R, where R is the carrier carbohydrate); used to study the survival rate in patients with lung carcinoma

Also Known As:

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 04/02/1991 - "MAb MIA-15-5 was established after immunization of mice with small cell lung carcinoma line PC7 and selected on the basis of inhibition of U937 and HEL cell migration. "
2.	Neoplasms (Cancer) 07/02/1992 - "We evaluated the possibility that expression of this antigen, which can be defined by the monoclonal antibody MIA-15-5, might be of prognostic value, as suggested by our previous observation that MIA-15-5 inhibits tumor-cell motility and metastasis. "
3.	Neoplasm Metastasis (Metastasis) 07/02/1992 - "We evaluated the possibility that expression of this antigen, which can be defined by the monoclonal antibody MIA-15-5, might be of prognostic value, as suggested by our previous observation that MIA-15-5 inhibits tumor-cell motility and metastasis. "
4.	Experimental Melanoma 04/02/1991 - "MAb MIA-15-5 reacted with 30-40% of high-metastatic variant BL6 of mouse melanoma B16 line but with only less than 5% of low-metastatic variant F1. "
5.	Lung Neoplasms (Lung Cancer) 07/02/1992 - "We used MIA-15-5 to stain tissue sections from 149 patients with primary lung cancer whose clinico-pathological histories were well documented. "

Related Drugs and Biologics

1.	Coloring Agents (Dyes)
2.	Antigens
3.	Monoclonal Antibodies